v3.26.1
Revenue- Incyte Corporation (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 24 Months Ended 102 Months Ended
Jun. 30, 2024
USD ($)
Jan. 31, 2022
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2017
USD ($)
performanceObligation
Dec. 31, 2018
USD ($)
Jun. 30, 2026
USD ($)
Dec. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
performanceObligation
Mar. 31, 2025
USD ($)
Sep. 30, 2023
USD ($)
Jul. 31, 2022
USD ($)
performanceObligation
Dec. 31, 2020
performanceObligation
Collaboration And Other Agreements [Line Items]                                
Total revenues     $ 32,832,000 $ 6,869,000 $ 39,553,000 $ 13,911,000                    
Deferred revenue, current     55,503,000   55,503,000         $ 55,503,000 $ 1,276,000          
Deferred revenue, net of current portion     0   0         0 $ 55,503,000          
Incyte Corporation | Incyte MGA012 Agreement                                
Collaboration And Other Agreements [Line Items]                                
Non-refundable upfront payment               $ 150,000,000                
Potential commercial milestone payments under agreement               330,000,000                
Potential development and regulatory milestone payments under agreement               210,000,000                
Development and regulatory milestones recognized             $ 100,000,000     $ 215,000,000            
Collaborative agreement transaction price               $ 154,000,000                
Variable consideration recognized                 $ 4,000,000              
Number of performance obligations | performanceObligation               2                
Incyte Corporation | Incyte Commercial Supply Agreement                                
Collaboration And Other Agreements [Line Items]                                
Number of performance obligations | performanceObligation                               1
Gilead | Gilead First Research Program                                
Collaboration And Other Agreements [Line Items]                                
Total revenues $ 3,300,000     5,600,000   11,000,000                    
Revenue, remaining performance obligation, amount                           $ 15,700,000    
Minimum | Incyte Corporation | Incyte MGA012 Agreement                                
Collaboration And Other Agreements [Line Items]                                
Potential proceeds from royalties (percent)               15.00%                
Maximum | Incyte Corporation | Incyte MGA012 Agreement                                
Collaboration And Other Agreements [Line Items]                                
Potential proceeds from royalties (percent)               24.00%                
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                                
Collaboration And Other Agreements [Line Items]                                
Total revenues     7,300,000 1,300,000 13,500,000 1,800,000   $ 150,000,000                
Revenues From License Agreements | Incyte Corporation | Incyte Commercial Supply Agreement                                
Collaboration And Other Agreements [Line Items]                                
Total revenues     10,300,000 0 14,400,000 400,000                    
RevenuesFromCMOAgreementsMember | Incyte Corporation                                
Collaboration And Other Agreements [Line Items]                                
Non-refundable upfront payment   $ 10,000,000                            
Annual Fixed Payments   14,400,000                            
Number of performance obligations | performanceObligation                       1     1  
RevenuesFromCMOAgreementsMember | Incyte Corporation | 2022 Agreement                                
Collaboration And Other Agreements [Line Items]                                
Total revenues       $ 13,300,000   $ 18,300,000                    
RevenuesFromCMOAgreementsMember | Incyte Corporation | 2025 Agreement                                
Collaboration And Other Agreements [Line Items]                                
Total revenues     $ 800,000   $ 4,700,000                      
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                                
Collaboration And Other Agreements [Line Items]                                
Annual Fixed Payments   $ 41,700,000                            
Additional Payments                         $ 13,500,000   $ 5,100,000  
Manufacturing Services | Incyte Corporation                                
Collaboration And Other Agreements [Line Items]                                
Extension term                             1 year  
Revenue, remaining performance obligation, amount                       $ 16,800,000        
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01                                
Collaboration And Other Agreements [Line Items]                                
Revenue, remaining performance obligation, expected timing of satisfaction   3 years                            
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01                                
Collaboration And Other Agreements [Line Items]                                
Revenue, remaining performance obligation, expected timing of satisfaction                       3 years